In addition, the demonstration that experimental “toolbox” tankyrase inhibitors can inhibit oncogenic Wnt signaling in colorectal tumour cells3 has driven the discovery of additional, drug-like, tankyrase inhibitors that could be used to target tumours that have constitutively active Wnt signaling, such as those with premature truncating mutations in the APC tumour suppressor protein4. Here, TNKS is linked to colorectal neoplasm.